Antihypertensive therapy optimization – case report Case report
Article Sidebar
Published:
Mar 31, 2024
Keywords:
hypertension, valsartan, treatment optimalization
Main Article Content
Abstract
Hypertension is one of the most important cardiovascular risk factors. Several therapeutic options are available that allow to adequately control the disease in the vast majority of cases. It is worth stressing that hypertension is a disease that often progresses with time and therefore requires regular adjustments in pharmacotherapy. Optimal disease control translates into reduction of the risk of serious ischemic events in the future.
Article Details
How to Cite
Krzowski, B., & Balsam, P. (2024). Antihypertensive therapy optimization – case report. Medycyna Faktow (J EBM), 17(1(62), 153-155. https://doi.org/10.24292/01.MF.0124.24
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Mancia G, Kreutz R, Brunström M et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023; 41(12): 1874-2071.
2. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1-86.
3. Fagard RH, Celis H, Thijs L et al. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009; 54(5): 1084-91.
4. Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003; 115(1): 41-6.
5. Salvetti M, Paini A, Bertacchini F et al. Changes in left ventricular geometry during antihypertensive treatment. Pharmacol Res. 2018; 134: 193-9.
6. Fogari R, Derosa G, Mugellini A et al. Effect of valsartan on adiponectine, leptin and resistine in hypertensive obese patients. High Blood Press Cardiovasc Prev. 2005; 18(5).
7. Barylski M. Walsartan w terapii nadciśnienia tętniczego – czy możemy leczyć hipotensyjnie, wpływając jednocześnie na zaburzenia związane z otyłością? Choroby Serca i Naczyń. 2015; 12(5): 274-81.
8. Chalmers J, Arima H, Woodward M et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014; 63(2): 259-64.
2. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1-86.
3. Fagard RH, Celis H, Thijs L et al. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009; 54(5): 1084-91.
4. Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003; 115(1): 41-6.
5. Salvetti M, Paini A, Bertacchini F et al. Changes in left ventricular geometry during antihypertensive treatment. Pharmacol Res. 2018; 134: 193-9.
6. Fogari R, Derosa G, Mugellini A et al. Effect of valsartan on adiponectine, leptin and resistine in hypertensive obese patients. High Blood Press Cardiovasc Prev. 2005; 18(5).
7. Barylski M. Walsartan w terapii nadciśnienia tętniczego – czy możemy leczyć hipotensyjnie, wpływając jednocześnie na zaburzenia związane z otyłością? Choroby Serca i Naczyń. 2015; 12(5): 274-81.
8. Chalmers J, Arima H, Woodward M et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014; 63(2): 259-64.